OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B. Nguyen, Melissa A. Reimers, Chamila Perera, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 15, pp. 3200-3210
Closed Access | Times Cited: 8
Charles B. Nguyen, Melissa A. Reimers, Chamila Perera, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 15, pp. 3200-3210
Closed Access | Times Cited: 8
Showing 8 citing articles:
Response to pembrolizumab in advanced prostate cancer with predictive biomarkers
Nicole Altomare, Yutai Li, Clayton Neill, et al.
The Oncologist (2025) Vol. 30, Iss. 3
Open Access
Nicole Altomare, Yutai Li, Clayton Neill, et al.
The Oncologist (2025) Vol. 30, Iss. 3
Open Access
Battlegrounds of treatment resistance: decoding the tumor microenvironment
Mobina Bayat, Javid Sadri Nahand
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Mobina Bayat, Javid Sadri Nahand
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers
Whi‐An Kwon, Jae Young Joung
Biomolecules (2025) Vol. 15, Iss. 5, pp. 625-625
Open Access
Whi‐An Kwon, Jae Young Joung
Biomolecules (2025) Vol. 15, Iss. 5, pp. 625-625
Open Access
Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial
Sandra van Wilpe, Iris S. H. Kloots, P.H.J. Slootbeek, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 2
Sandra van Wilpe, Iris S. H. Kloots, P.H.J. Slootbeek, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 2
Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer
Francesca Zacchi, Wassim Abida, Emmanuel S. Antonarakis, et al.
European Urology Oncology (2024)
Closed Access | Times Cited: 2
Francesca Zacchi, Wassim Abida, Emmanuel S. Antonarakis, et al.
European Urology Oncology (2024)
Closed Access | Times Cited: 2
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer
Yang Yang, Michelle L. Badura, Patrick C. O’Leary, et al.
Nature Cancer (2024)
Closed Access | Times Cited: 1
Yang Yang, Michelle L. Badura, Patrick C. O’Leary, et al.
Nature Cancer (2024)
Closed Access | Times Cited: 1
Elusive Biomarkers of Sensitivity to Combined PD1/CTLA4 Blockade in Metastatic Castration-Resistant Prostate Cancer
E.S. Antonarakis
Annals of Oncology (2024)
Closed Access
E.S. Antonarakis
Annals of Oncology (2024)
Closed Access
Roles of CDK12 mutations in PCa development and treatment
Chen Jiang, Zhe Hong, Shiwei Liu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189247-189247
Closed Access
Chen Jiang, Zhe Hong, Shiwei Liu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189247-189247
Closed Access
New insights into the dule roles CDK12 in human cancers: mechanisms and interventions for cancer therapy
Wei Dai, Dong Xie, Hao Huang, et al.
Journal of Pharmaceutical Analysis (2024), pp. 101173-101173
Open Access
Wei Dai, Dong Xie, Hao Huang, et al.
Journal of Pharmaceutical Analysis (2024), pp. 101173-101173
Open Access
